首页> 外文期刊>Otology and neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology >Intratympanic dexamethasone and hyaluronic acid in patients with low-frequency and Meniere's-associated sudden sensorineural hearing loss.
【24h】

Intratympanic dexamethasone and hyaluronic acid in patients with low-frequency and Meniere's-associated sudden sensorineural hearing loss.

机译:Intratympanic地塞米松和透明质酸低频患者和突然的感音神经性听力美尼尔综合症有关的损失。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Steroids are widely used for the treatment of cochleovestibular disorders. Direct steroid application in the middle ear cavity, when combined with a round window membrane permeability-modulating substance, increases the level of the steroid reaching the target cells. We measured hearing in patients with idiopathic isolated low-frequency sensorineural hearing loss and in patients with sudden sensorineural hearing loss and a history of Meniere's disease. Contradictory reports about effectiveness of intratympanic steroid therapy on vertigo control and hearing improvement in patients with Meniere's disease exist in the literature. METHODS: Eighteen patients with isolated low-frequency idiopathic sudden sensorineural hearing loss and 21 patients with sudden sensorineural hearing loss and a history of Meniere's disease were prospectively evaluated. The acute effect of the intratympanic application of dexamethasone with hyaluronic acid on hearing outcome after failure of an initial standard treatment with intravenous steroid and vasoactive substances was assessed. Evaluation was based on standard pure-tone audiometry findings. RESULTS: After intratympanic injection of dexamethasone and hyaluronic acid, 14 of the 18 patients with isolated low-frequency sensorineural hearing loss showed a significant improvement in hearing. After intratympanic therapy, 15 patients with a previous history of Meniere's disease and idiopathic isolated low-frequency sensorineural hearing loss showed an improvement in hearing on pure-tone audiometry, four remained unchanged, and two showed a tendency toward a slight deterioration. CONCLUSION: Intratympanic combined dexamethasone/hyaluronic acid application provides a reliable and safe therapeutic option for improvement of hearing in patients with isolated low-frequency idiopathic sudden sensorineural hearing loss or sensorineural hearing loss resulting from Meniere's disease who have failed intravenous steroid and vasoactive treatments.
机译:背景:类固醇广泛应用的cochleovestibular失调的治疗。类固醇的应用程序在中耳腔,当加上一个圆形窗口膜permeability-modulating物质,增加了类固醇水平达到目标细胞。我们测量特发性患者的听力隔离低频感音神经性听力损失患者和突然的感音神经性听力损失和梅尼埃病(又名内耳眩晕病)的历史。相互矛盾的报道效果intratympanic类固醇治疗眩晕的控制患者和听力提高梅尼埃病(又名内耳眩晕病)在文献中存在。方法:18例孤立低频特发性突感音神经性听力损失患者和21突然感音神经性听力损失和的历史梅尼埃病(又名内耳眩晕病)是前瞻性评估。的急性影响intratympanic应用程序地塞米松与透明质酸的听证会结果失败后的初步标准用静脉注射类固醇治疗和血管活性的物质评估。标准的纯音听力测定结果。intratympanic后注射地塞米松透明质酸,14的18例隔离低频感音神经性听力损失显示显著改善听力。intratympanic治疗后,患者15以前的梅尼埃病(又名内耳眩晕病)和历史特发性隔离低频感音神经性听力损失显示听证会上的改善纯音听力测定,四个保持不变,和两个显示轻微的倾向恶化。地塞米松/透明质酸的应用程序提供了一个可靠和安全的治疗选择改善患者的听力隔离低频特发性突感音神经性听力损失或感音神经性造成听力损失梅尼埃病(又名内耳眩晕病)没有静脉注射类固醇和血管活性的吗治疗方法。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号